Navigation Links
Protein may represent a switch to turn off B cell lymphoma
Date:5/7/2012

Researchers studying the molecular signals that drive a specific type of lymphoma have discovered a key biological pathway leading to this type of cancer. Cancerous cells have been described as being "addicted" to certain oncogenes (cancer-causing genes), and the new research may lay the groundwork for breaking that addiction and effectively treating aggressive types of B cell lymphoma.

B cell lymphomas, which occur both in children and adults, are cancers that attack B cells in the immune system.

"Our research suggests ways to devise more specific therapies to selectively kill tumor cells in a subset of lymphomas," said study leader Andrei Thomas-Tikhonenko, Ph.D., an oncology researcher at The Children's Hospital of Philadelphia.

The study, conducted in animal cells and human cell cultures, appeared May 1 in The Journal of Clinical Investigation.

An oncogene is a type of gene that normally produces a protein active in cell growth or regulation. However, when the gene is mutated or otherwise overproduced, it can cause cancer. One family of oncogenes is called MYC, and the current study focused on how the MYC oncogene drives B cell lymphoma. MYC codes for Myc, a type of protein called a transcription factor. At high levels, Myc causes the uncontrolled cell growth that is a hallmark of cancer.

The researchers focused on the crucial role of the cell surface receptor CD19, a protein residing on the surface of all B cells that normally recognizes foreign invaders. "We found that CD19 is absolutely required to stabilize the Myc protein," said Thomas-Tikhonenko. "When Myc is stable and present in high levels, it fuels cancer." Patients with high levels of the Myc protein are more likely to die of lymphoma.

Patients with high levels of Myc also had high levels of CD19, and the current study describes a previously unknown molecular pathway that depends on CD19. It also implicates CD19 as a molecular on-off switch on that pathway. Usually, said Thomas-Tikhonenko, when you inhibit one pathway, another pathway compensates to produce the same end result. But in this case, there is no such redundant pathway: "Without CD19, there is no Myc," he added, "so controlling that on-off switch could represent a powerful tool against lymphoma."

The findings are particularly relevant, said Thomas-Tikhonenko, to current oncology clinical trials that are testing antibodies that act broadly against the CD19 receptor. Such antibodies kill all B cells, and thus weaken the immune system. His study suggests that understanding the CD19 pathway could enable researchers to design a more specific therapy that selectively kills tumor cells while sparing healthy B cells.

Further studies in his lab, he added, will further investigate these molecular pathways and how to translate this knowledge into future anti-cancer treatments.


'/>"/>

Contact: John Ascenzi
Ascenzi@email.chop.edu
267-426-6055
Children's Hospital of Philadelphia
Source:Eurekalert

Related medicine news :

1. New and Delicious, Almond Butter Filled, Cookie Bites With 35.7% Protein to Help Manage Weight and Build Muscle
2. Research highlights role of protein pair in obesity regulation
3. Urine protein test might help diagnose kidney damage from lupus, UT Southwestern researchers find
4. Smithfield, United Food and Commercial Workers Union, and Food Networks Paula Deen to Deliver 150,000 Servings of Protein to San Francisco Food Bank
5. Protein Sciences Corporation Announces Profitable and Cash Flow Positive Results for 2009 and Management Realignment
6. Protein Appears Key to Intestinal Balance
7. SIBLING proteins may predict oral cancer
8. Damaged protein identified as early diagnostic biomarker for Alzheimers disease in healthy adults
9. Cells of aggressive leukemia hijack normal protein to grow
10. Omega Protein Comments on California Lawsuit Alleging Fish Oil Contaminants
11. Proteins May Predict Spread of Colon Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/12/2018)... ... September 12, 2018 , ... Today, Sterling , a rope ... attempted the first unassisted adaptive climb of the Lotus Flower Tower in Canada’s Cirque ... difficult for him to lead, the duo decided to persevere and with some assistance ...
(Date:9/7/2018)... ... September 07, 2018 , ... Modere, ... with a presence worldwide, today announced that its Chief Executive Officer, Asma Ishaq, ... Ms. Ishaq will be presented the award on Friday, September 7, at the ...
(Date:9/3/2018)... Huntingdon Valley, PA (PRWEB) , ... September 03, 2018 , ... ... Maples and other hardwoods should be in full leaf and green through September. When ... shuts down for winter before other trees of the same type. Giroud Tree ...
(Date:9/1/2018)... ... August 31, 2018 , ... SignatureCare Emergency Center is ... for the Fall semester to a deserving student. Get your applications in now as ... was awarded to Hanna Wu who is a medical student at Texas Southern University. ...
(Date:8/31/2018)... ... 31, 2018 , ... MedMark Treatment Centers Kentwood, a BayMark ... from 1:00-3:00 pm. MedMark invites the community to explore the world ... meet our staff and learn more about medication-assisted treatment services. MedMark Kentwood can ...
Breaking Medicine News(10 mins):
(Date:9/7/2018)... ... September 06, 2018 , ... CTL Medical Corporation has entered ... spine business, which includes its complete portfolio of spine-related patents and 510ks, as ... it. The deal will make CTL Medical the world’s exclusive provider of silicon ...
(Date:9/7/2018)... ... ... New York City is currently the epicenter of the tennis world, as ... fourth and final jewel in the 2018 grand slam crown – The US Open. ... the players’ footwork be highlighted. , “Today’s tennis isn’t that of your grandmother,” says ...
(Date:9/1/2018)... ... August 31, 2018 , ... New England College of ... a Vice President/ Dean of Academic Affairs. Reporting directly to the President of ... the chief academic officer responsible for the faculty and the related administrative departments ...
Breaking Medicine Technology: